# TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

> **NCT02663271** · PHASE2 · TERMINATED · sponsor: **University of Florida** · enrollment: 10 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Glioblastoma
- Malignant Glioma
- GBM

## Interventions

- **DRUG:** Bevacizumab
- **DEVICE:** Optune
- **OTHER:** Brain MRI
- **OTHER:** Quality of Life Questionnaires

## Key facts

- **NCT ID:** NCT02663271
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-19
- **Primary completion:** 2021-06-11
- **Final completion:** 2021-06-11
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** stagnant enrollment
- **Last updated:** 2022-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02663271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02663271, "TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02663271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*